{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-060795","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2024-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.870046+00:00","generated_at":"2026-05-31T21:20:40.538737+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"NKGen Biotech appoints Dr. Marco Gottardis to Board of Directors","bullets":["Dr. Gottardis fills Class I director vacancy created by Alana McNulty's resignation, effective July 11, 2024.","Appointed to Audit, Compensation, and Nominating committees; annual retainer of $40,000 plus committee retainers.","Received sign-on option for 300,000 shares at $2.00 per share, vesting monthly over three years.","Background: former VP of Oncology Innovation at Janssen (JNJ) and Senior VP at Replay Bio Holdings."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-060795","json":"https://secwatch.observer/filing/0001213900-24-060795.json","markdown":"https://secwatch.observer/filing/0001213900-24-060795.md","text":"https://secwatch.observer/filing/0001213900-24-060795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/ea0209333-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:20:40.538737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"61d7fffe63","claim":"Dr. Marco Gottardis was elected as Director at NKGen Biotech, Inc..","evidence_excerpt":"On July 11, 2024, the Board, following a recommendation from the N&CG Committee, unanimously elected to have Dr. Marco Gottardis fill, effective immediately, the Class I director vacancy created by Ms. McNulty’s resignation and that Dr. Gottardis shall hold such position as a Class I director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bdc687deb4","claim":"Alana McNulty resigned as Director at NKGen Biotech, Inc..","evidence_excerpt":"Ms. Alana McNulty notified the Board of Directors of the Company (the “Board”) of her intention to resign as a director of the Company and as a member of our Audit Committee (the “Audit Committee”), Compensation Committee (the “Compensation Committee”) and Nomination and Corporate Governance Committee (the “N&CG Committee”), effective February 4, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390024060795/0001213900-24-060795-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}